- Home
- ZEUS vs RIGL Comparison
ZEUS vs RIGL Comparison
Compare ZEUS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEUS
- RIGL
- Stock Information
- Founded
- ZEUS 1954
- RIGL 1996
- Country
- ZEUS United States
- RIGL United States
- Employees
- ZEUS N/A
- RIGL N/A
- Industry
- ZEUS Metal Fabrications
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ZEUS Industrials
- RIGL Health Care
- Exchange
- ZEUS Nasdaq
- RIGL Nasdaq
- Market Cap
- ZEUS 352.6M
- RIGL 335.5M
- IPO Year
- ZEUS 1994
- RIGL 2000
- Fundamental
- Price
- ZEUS $33.71
- RIGL $38.85
- Analyst Decision
- ZEUS Buy
- RIGL Buy
- Analyst Count
- ZEUS 1
- RIGL 5
- Target Price
- ZEUS $38.00
- RIGL $38.20
- AVG Volume (30 Days)
- ZEUS 55.6K
- RIGL 995.6K
- Earning Date
- ZEUS 10-30-2025
- RIGL 08-05-2025
- Dividend Yield
- ZEUS 1.90%
- RIGL N/A
- EPS Growth
- ZEUS N/A
- RIGL N/A
- EPS
- ZEUS 1.23
- RIGL 5.43
- Revenue
- ZEUS $1,878,204,000.00
- RIGL $267,921,000.00
- Revenue This Year
- ZEUS $0.48
- RIGL $59.93
- Revenue Next Year
- ZEUS $2.77
- RIGL N/A
- P/E Ratio
- ZEUS $27.48
- RIGL $7.15
- Revenue Growth
- ZEUS N/A
- RIGL 105.62
- 52 Week Low
- ZEUS $26.32
- RIGL $12.66
- 52 Week High
- ZEUS $43.60
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- ZEUS 58.07
- RIGL 68.57
- Support Level
- ZEUS $33.15
- RIGL $39.00
- Resistance Level
- ZEUS $34.07
- RIGL $42.08
- Average True Range (ATR)
- ZEUS 0.81
- RIGL 2.32
- MACD
- ZEUS 0.23
- RIGL -0.37
- Stochastic Oscillator
- ZEUS 86.91
- RIGL 53.26
About ZEUS Olympic Steel Inc.
Olympic Steel Inc provides metals processing and distribution services in the United States. The company operates in three reportable segments; specialty metals flat products, carbon flat products, and tubular and pipe products. It specializes in the processing and distribution of large volumes of carbon, aluminum, and stainless steel flat-rolled sheet, coils, plates, bars, and fabricated parts. The group serves various industries such as industrial machinery and equipment manufacturers, automobile manufacturers and suppliers, and transportation equipment manufacturers. The company generates majority of the revenue from carbon flat products.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.